Regeneron Pharmaceuticals Archives - DelveInsight

Regeneron Pharmaceuticals

Sinusitis-Disease-Overview-Signs-and-Treatments
Sinusitis: Something More Troublesome Than Just Cold

Cold can make anyone cheerless and miserable, however, having Sinusitis is another story. Also known as rhinosinusitis, Sinusitis makes a person suffer from a stuffy nose, blocked nasal passages, ...


Latest Pharma Happenings
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva̵...

Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19.  Regeneron is running two trials simultaneously, one for prevention and oth...


pharma news
Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVI...

Sage Therapeutics seeking out to save flunked depression drug Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The ...


Pharma News
Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hy...

Activated immune cells responsible for improving age-related diseasesThe main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL-5. There has been res...


Allergic rhinitis market
Allergic rhinitis market: How common is Hay fever?

Allergic diseases, such as allergic rhinitis (hay fever), food allergy, and eczema, are common allergies that affect people from all over the world. As per CDC, allergies are one of the top ten ca...


World Pharma News
Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan

Sanifit raises USD 80.9 M to advance Calciphylaxis PipelineSanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( €72.2 million ) in total private fundraising. The ...


Notizia

Anylam, Regeneron to broaden the scope of R&D in PharmaAlnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various target...


SANOFI
Cholesterol drug Praluent successful in reducing heart risk

Sanofi and Regeneron Pharmaceuticals got effective results in reducing the risk of major adverse heart events in a clinical study of nearly 19,000 patients with the help of cholesterol drug Praluen...


Prosecutors rope Pfizer; Pharma groups to FDA; Regeneron simulates; Otsuka & Lundbeck revive...

Prosecutors rope Pfizer into fast-growing copay assistance probe After first focusing on biotech and speciality pharma, the feds have made their way to Big Pharma, with the New York drug giant join...


Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus ...

Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 busine...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.